Generic Name and Formulations:
Zolmitriptan 2.5mg, 5mg; orally-disintegrating tabs; orange flavor; contains phenylalanine.
Impax Laboratories, Inc.
Indications for ZOMIG-ZMT:
Acute treatment of migraine.
≥18yrs: Initially 1.25–2.5mg; max recommended single dose: 5mg. If headache returns, may repeat after 2 hrs; max 10mg/day. Reevaluate if no response after 1st dose. The safety of treating an average of more than 3 headaches in a 30-day period has not been established. Moderate to severe hepatic impairment: 1.25mg; severe hepatic impairment: max 5mg/day. Concomitant cimetidine: max single dose: 2.5mg, not to exceed 5mg in 24hr period. ZMT: dissolve on tongue and swallow without water.
<18yrs: not recommended.
Ischemic heart disease (angina pectoris, history of MI, documented silent ischemia). Coronary artery vasospasm (eg, Prinzmetal's angina). Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders. History of stroke, TIA, or hemiplegic or basilar migraine. Peripheral vascular disease. Ischemic bowel disease. Uncontrolled hypertension. Within 24 hours of ergot-type drugs or other 5-HT1 agonists. During or within 2 weeks after discontinuing MAOIs (type A).
Confirm diagnosis. Exclude underlying cardiovascular disease, supervise 1st dose, and consider monitoring ECG in patients with likelihood of unrecognized coronary disease (eg, postmenopausal women, men over age 40, hypertension, hypercholesterolemia, obesity, diabetes, smokers, strong family history). Discontinue if disturbances in cardiac rhythm occur. Rule out vasospastic reaction before receiving additional doses. Monitor cardiovascular function in long-term intermittent use. Overuse may lead to exacerbation of headache (medication overuse headache). Hepatic dysfunction. Monitor BP. Elderly. Pregnancy (Cat.C). Nursing mothers.
MAOIs (type A), methysergide, other ergotamines, other 5-HT1 agonists: see Contraindications. Serotonin syndrome with SSRIs, SNRIs, TCAs, MAOIs; discontinue if suspected. Absorption and half-life increased by cimetidine.
Selective 5-HT1B/1D receptor agonist.
Neck/throat/jaw pain/tightness/pressure, dizziness, paresthesia, asthenia, somnolence, warm/cold sensation, nausea, heaviness sensation, dry mouth; rare: serious cardiac events. Nasal spray: also taste disturbances, local reactions.
Tabs (YES); ZMT tabs, sprayer (NO)
Tabs, ZMT tabs 2.5mg—6; Tabs, ZMT tabs 5mg—3; Single-dose sprayer—6
Renal and Urology News Articles
- Tamsulosin Improves Clearance of Large Distal Ureteral Stones
- Calciphylaxis in CKD Patients Linked to Hypercoagulable Conditions
- Post-Parathyroidectomy Calcium Requirement Linked to Preop ALP
- Sucroferric Oxyhydroxide Efficacy Similar to That of Sevelamer
- Ceruloplasmin a Possible Marker of CKD in Sickle Cell Anemia
- Cytoreductive Nephrectomy Benefits for Metastatic RCC Demonstrated
- Phosphorus Content Higher in Packaged Meats Listing Phosphate Additives
- High Intakes of Teas, Peas, Soybeans May Increase Prostate Cancer Risk
- More Intense Treatment, Worse Quality of Life in Diabetes
- Hemodialysis CRBSI Outcomes Unaffected by Distance to Nephrologists
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)